$4.7219
-0.2381[-4.80%]
Last update: 2:40PM Get Real Time Here
ADC Therapeutics
(NYSE:ADCT)ADC Therapeutics Stock (NYSE:ADCT), Analyst Ratings, Price Targets, Predictions
ADC Therapeutics SA has a consensus price target of $19.38, established from looking at the 45 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Guggenheim, and Guggenheim on April 15, 2024, April 5, 2024, and March 28, 2024. With an average price target of $6.67 between HC Wainwright & Co., Guggenheim, and Guggenheim, there's an implied 41.19% upside for ADC Therapeutics SA from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
RBC Capital
TD Cowen
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for ADC Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/15/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 90.6% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 04/05/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | — | Guggenheim | Michael Schmidt | — | Reiterates | → Buy | Get Alert |
| 03/28/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 132.96% | Guggenheim | Michael Schmidt | → $11 | Initiates | → Buy | Get Alert |
| 03/14/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 69.42% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 03/06/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 90.6% | HC Wainwright & Co. | Robert Burns | → $9 | Reiterates | Buy → Buy | Get Alert |
| 02/26/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 69.42% | RBC Capital | Gregory Renza | $6 → $8 | Maintains | Outperform | Get Alert |
| 02/20/2024 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 90.6% | HC Wainwright & Co. | Robert Burns | $3 → $9 | Maintains | Buy | Get Alert |
| 11/20/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | -36.47% | HC Wainwright & Co. | Robert Burns | $12 → $3 | Maintains | Buy | Get Alert |
| 11/09/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | — | TD Cowen | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/08/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 27.07% | RBC Capital | Gregory Renza | $7 → $6 | Maintains | Outperform | Get Alert |
| 09/19/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 154.13% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 69.42% | RBC Capital | Gregory Renza | $9 → $8 | Maintains | Outperform | Get Alert |
| 08/10/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | — | JP Morgan | Brian Cheng | — | Upgrade | Underweight → Neutral | Get Alert |
| 08/09/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 90.6% | RBC Capital | Gregory Renza | $10 → $9 | Maintains | Outperform | Get Alert |
| 07/25/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 154.13% | HC Wainwright & Co. | Robert Burns | → $12 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | -57.64% | Morgan Stanley | Jeffrey Hung | $5 → $5 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/20/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 154.13% | HC Wainwright & Co. | Robert Burns | $20 → $12 | Maintains | Buy | Get Alert |
| 05/10/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | 111.78% | RBC Capital | Gregory Renza | $12 → $10 | Maintains | Outperform | Get Alert |
| 04/24/2023 | ADCT | Buy Now | ADC Therapeutics | $4.72 | -57.64% | B of A Securities | Tazeen Ahmad | $7 → $2 | Downgrade | Neutral → Underperform | Get Alert |
FAQ
What is the target price for ADC Therapeutics (ADCT)?
The latest price target for ADC Therapeutics (NYSE: ADCT) was reported by HC Wainwright & Co. on April 15, 2024. The analyst firm set a price target for $9.00 expecting ADCT to rise to within 12 months (a possible 90.60% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ADC Therapeutics (ADCT)?
The latest analyst rating for ADC Therapeutics (NYSE: ADCT) was provided by HC Wainwright & Co., and ADC Therapeutics reiterated their buy rating.
When was the last upgrade for ADC Therapeutics (ADCT)?
The last upgrade for ADC Therapeutics SA happened on August 10, 2023 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for ADC Therapeutics SA.
When was the last downgrade for ADC Therapeutics (ADCT)?
The last downgrade for ADC Therapeutics SA happened on November 9, 2023 when TD Cowen changed their price target from N/A to N/A for ADC Therapeutics SA.
When is the next analyst rating going to be posted or updated for ADC Therapeutics (ADCT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADC Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADC Therapeutics was filed on April 15, 2024 so you should expect the next rating to be made available sometime around April 15, 2025.
Is the Analyst Rating ADC Therapeutics (ADCT) correct?
While ratings are subjective and will change, the latest ADC Therapeutics (ADCT) rating was a reiterated with a price target of $0.00 to $9.00. The current price ADC Therapeutics (ADCT) is trading at is $4.72, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.